<\/p>\n
AB Komisyonu, \u00fcye 27 \u00fclke ad\u0131na Kovid-19 a\u015f\u0131lar\u0131 al\u0131m\u0131 i\u00e7in BioNTech-Pfizer ile yap\u0131lan s\u00f6zle\u015fme de\u011fi\u015fikli\u011fi g\u00f6r\u00fc\u015fmeleri sonucunda anla\u015fma sa\u011fland\u0131\u011f\u0131n\u0131 duyurdu.<\/p>\n
A\u00e7\u0131klamada, AB ve a\u015f\u0131 geli\u015ftiren BioNTech-Pfizer’\u0131n yeni ihtiya\u00e7lar do\u011frultusunda s\u00f6zle\u015fmedeki de\u011fi\u015fikliklerde uzla\u015ft\u0131\u011f\u0131 belirtildi.<\/p>\n
Mevcut a\u015f\u0131 tedarik s\u00f6zle\u015fmesinde yap\u0131lan de\u011fi\u015fikli\u011fin d\u00fczelen epidemiyolojik durumu dikkate ald\u0131\u011f\u0131 ifade edilen a\u00e7\u0131klamada, gelecekte endi\u015fe duyulan Kovid-19 varyantlar\u0131n\u0131n ortaya \u00e7\u0131kmas\u0131 durumunda a\u015f\u0131ya eri\u015fimin s\u00fcrece\u011fi kaydedildi.<\/p>\n
A\u00e7\u0131klamada, de\u011fi\u015fiklikle mevcut a\u015f\u0131 s\u00f6zle\u015fmesinde \u00fcye \u00fclkeler taraf\u0131ndan al\u0131nacak a\u015f\u0131 dozu miktar\u0131n\u0131n azald\u0131\u011f\u0131na i\u015faret edilerek, belirli bir \u00fccret kar\u015f\u0131l\u0131\u011f\u0131nda ba\u015flang\u0131\u00e7 s\u00f6zle\u015fmesindeki dozlar\u0131n opsiyonlu doza d\u00f6n\u00fc\u015ft\u00fcr\u00fclece\u011fi bildirildi.<\/p>\n
\u00dcye \u00fclkelerin a\u015f\u0131lar\u0131 teslim alabilece\u011fi s\u00fcrenin de uzat\u0131ld\u0131\u011f\u0131 belirtilen a\u00e7\u0131klamada, bu dozlar\u0131n 4 y\u0131l sonras\u0131na kadar tedarik edilebilece\u011fi ifade edildi.<\/p>\n
AB \u00fclkeleri, azalan a\u015f\u0131 talebi nedeniyle Komisyon’un \u00fcreticilerle yapt\u0131\u011f\u0131 Kovid-19 a\u015f\u0131 s\u00f6zle\u015fmelerinde de\u011fi\u015fiklik talep ediyordu.<\/p>\n
AB, 2021’de BioNTech-Pfizer ile 2023 y\u0131l\u0131 sonuna kadar 900 milyon dozu opsiyonlu, toplam 1,8 milyar doz Kovid-19 a\u015f\u0131s\u0131 al\u0131m\u0131na y\u00f6nelik 3’\u00fcnc\u00fc s\u00f6zle\u015fmeyi imzalam\u0131\u015ft\u0131.<\/p>\n
Talep olmad\u0131\u011f\u0131 i\u00e7in bu s\u00f6zle\u015fmedeki 900 milyon dozun yakla\u015f\u0131k yar\u0131ya yak\u0131n\u0131 teslim edilmedi.<\/p>\n
Ayr\u0131ca, AB s\u00f6zle\u015fmedeki ek al\u0131m opsiyonunu da uygulamaya koymad\u0131.<\/p>\n
S\u00f6zle\u015fme de\u011fi\u015fikli\u011fiyle AB’nin sat\u0131n alma taahh\u00fcd\u00fcnde bulundu\u011fu doz miktar\u0131 d\u00fc\u015f\u00fcyor. Ancak AB iptal edilen her doz i\u00e7in bir \u00fccret \u00f6demek zorunda kal\u0131yor.<\/p>\n
S\u00f6z konusu a\u015f\u0131lar\u0131n fiyat\u0131 ve iptal i\u00e7in \u00f6denecek rakam ise payla\u015f\u0131lm\u0131yor.<\/p>\n
AB Komisyonu, Kovid-19 salg\u0131n\u0131yla m\u00fccadelede baz\u0131 ila\u00e7 ve a\u015f\u0131 \u00fcreticilerinden y\u00fcksek miktarlarda a\u015f\u0131 temin etmi\u015fti. Komisyon, Kovid-19 a\u015f\u0131 temini i\u00e7in en y\u00fckl\u00fc s\u00f6zle\u015fmesini Pfizer-BioNTech ile yapm\u0131\u015ft\u0131.<\/p>\n